This document summarizes the HIV/AIDS research funding and priorities of the National Institute on Drug Abuse (NIDA). It shows that in FY13, 55% of NIDA's HIV/AIDS budget went to behavioral and social science research, while other areas like therapeutics and vaccines received less. The document outlines NIDA's research priorities in prevention, treatment, co-morbidities, and related areas. It also lists new funding opportunities and initiatives for FY15-16 that aim to enhance HIV prevention, care, and treatment for at-risk groups including substance users.
RADx-UP CDCC presentation for the NIH Disaster Interest GroupWarren Kibbe
Presentation on the RADx-Underserved Populations Coordination and Data Collection Center with an emphasis on how it will help understand and reduce the disparities associated with the COVDI-19 pandemic
Dr. Julie Lyn Hall, WHO Country Representative for the Philippines, discusses the strategies of the WPRO in handling and preventing EIDs like Ebola and MERS-CoV in our region
RADx-UP CDCC presentation for the NIH Disaster Interest GroupWarren Kibbe
Presentation on the RADx-Underserved Populations Coordination and Data Collection Center with an emphasis on how it will help understand and reduce the disparities associated with the COVDI-19 pandemic
Dr. Julie Lyn Hall, WHO Country Representative for the Philippines, discusses the strategies of the WPRO in handling and preventing EIDs like Ebola and MERS-CoV in our region
Davey Smith, MD, MAS
Professor of Medicine
Chief, Division of Infectious Diseases and Global Public Health
Co-Director, San Diego Center for AIDS Research (CFAR)
Department of Medicine
University of California, San Diego
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia
Dr Neil Buckholtz , Director of Neuroscience, the National Institute on Aging (NIA), National Institutes of Health (NIH)
Why Precision Medicine and Personalized Healthcare and Why Now? Links to Canada’s Rare Disease Strategy The Future is Now
1) Marc LePage, Genome Canada
2) Michael Duong, Roche
3) Danica Stanimirovic, National Research Council
4) Daniel Gaudet, University of Montreal
5) Christine Dalgleish, Patient Perspective
6) Jamie Bruce, Khure Health
The views expressed in the presentations are that of the author and do not necessarily reflect the views of the Government of Canada. Presentations are shared in the original format received from the presenter.
Presentations given at the Conference to Develop a Federal Framework on Lyme Disease are the property of the author, unless otherwise cited. If you reference the author's work, you must give the author credit by naming the author and their work as well as the place and date it was presented.
For more information, contact the Lyme Disease Conference Secretariat at maladie_lyme_disease@phac-aspc.gc.ca
The views expressed in the presentations are that of the author and do not necessarily reflect the views of the Government of Canada. Presentations are shared in the original format received from the presenter.
Presentations given at the Conference to Develop a Federal Framework on Lyme Disease are the property of the author, unless otherwise cited. If you reference the author's work, you must give the author credit by naming the author and their work as well as the place and date it was presented.
For more information, contact the Lyme Disease Conference Secretariat at maladie_lyme_disease@phac-aspc.gc.ca
Zika Prevention Approaches in Jamaica UWI_Markcomm
Shaping the Caribbean's response to Zika, UWI’s Zika Task Force (www.uwi.edu/zika) is gathering and providing expert advice to develop a strategic, scientific approach for tackling the Zika virus.
Identifying High Performing Sites and Engaging PatientsMedpace
One of the biggest challenges facing any clinical trial is how to identify the sites with the greatest potential to engage and retain patients. Applying decades of experience to the topic, Medpace experts will share considerations, lessons-learned and best practices for developing patient recruitment strategies to put you on the path for optimal success.
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
Leaping the Hurdles and Navigating the Maze: Understanding the NIHHopkinsCFAR
Susan Newcomer, PhD, MS
Health Scientist Administrator, Population Dynamics
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Davey Smith, MD, MAS
Professor of Medicine
Chief, Division of Infectious Diseases and Global Public Health
Co-Director, San Diego Center for AIDS Research (CFAR)
Department of Medicine
University of California, San Diego
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia
Dr Neil Buckholtz , Director of Neuroscience, the National Institute on Aging (NIA), National Institutes of Health (NIH)
Why Precision Medicine and Personalized Healthcare and Why Now? Links to Canada’s Rare Disease Strategy The Future is Now
1) Marc LePage, Genome Canada
2) Michael Duong, Roche
3) Danica Stanimirovic, National Research Council
4) Daniel Gaudet, University of Montreal
5) Christine Dalgleish, Patient Perspective
6) Jamie Bruce, Khure Health
The views expressed in the presentations are that of the author and do not necessarily reflect the views of the Government of Canada. Presentations are shared in the original format received from the presenter.
Presentations given at the Conference to Develop a Federal Framework on Lyme Disease are the property of the author, unless otherwise cited. If you reference the author's work, you must give the author credit by naming the author and their work as well as the place and date it was presented.
For more information, contact the Lyme Disease Conference Secretariat at maladie_lyme_disease@phac-aspc.gc.ca
The views expressed in the presentations are that of the author and do not necessarily reflect the views of the Government of Canada. Presentations are shared in the original format received from the presenter.
Presentations given at the Conference to Develop a Federal Framework on Lyme Disease are the property of the author, unless otherwise cited. If you reference the author's work, you must give the author credit by naming the author and their work as well as the place and date it was presented.
For more information, contact the Lyme Disease Conference Secretariat at maladie_lyme_disease@phac-aspc.gc.ca
Zika Prevention Approaches in Jamaica UWI_Markcomm
Shaping the Caribbean's response to Zika, UWI’s Zika Task Force (www.uwi.edu/zika) is gathering and providing expert advice to develop a strategic, scientific approach for tackling the Zika virus.
Identifying High Performing Sites and Engaging PatientsMedpace
One of the biggest challenges facing any clinical trial is how to identify the sites with the greatest potential to engage and retain patients. Applying decades of experience to the topic, Medpace experts will share considerations, lessons-learned and best practices for developing patient recruitment strategies to put you on the path for optimal success.
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
Leaping the Hurdles and Navigating the Maze: Understanding the NIHHopkinsCFAR
Susan Newcomer, PhD, MS
Health Scientist Administrator, Population Dynamics
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Scientific Merit Paper Scoring GuideEvaluates the scientific mer.docxbagotjesusa
Scientific Merit Paper Scoring Guide
Evaluates the scientific merit of the article by analyzing how the research advances the scientific knowledge base. Evaluates the scientific merit of the article by analyzing how the research contributes to research theory and the field of study. Evaluates the scientific merit of the article by analyzing the scientific methods. Analyzes the validity and reliability of a selected research study and elaborates on how it contributes to scientific merit. Analyzes the effectiveness of strategies selected for addressing ethical concerns in the design of a research study. Communicates in a manner that is completely scholarly, professional, and consistent with expectations for members of the identified field of study, and uses APA style and formatting with few or no errors.
R
O
d
C
a
b
c
a
A
R
R
2
A
K
R
I
S
H
I
S
I
c
i
s
c
a
d
e
C
o
H
C
f
0
d
International Journal of Drug Policy 21 (2010) 289–295
Contents lists available at ScienceDirect
International Journal of Drug Policy
j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / d r u g p o
esearch paper
pportunities for enhancing and integrating HIV and drug services for
rug using vulnerable populations in South Africa
harles D.H. Parry a,b,∗, Petal Petersen a, Tara Carney a, Richard Needle c
Alcohol & drug Abuse Research Unit, Medical Research Council, South Africa
Department of Psychiatry, Stellenbosch University, South Africa
Pangaea Global AIDS Foundation, USA
r t i c l e i n f o
rticle history:
eceived 25 July 2009
eceived in revised form
0 November 2009
ccepted 24 November 2009
eywords:
apid assessment
llicit drugs
ex risk
IV
ntegrated services
outh Africa
a b s t r a c t
Background: Little has been done to improve the integration of drug use and HIV services in sub-Saharan
Africa where substance use and HIV epidemics often co-exist.
Methods: Data were collected using rapid assessment methods in two phases in Cape Town, Durban
and Pretoria, South Africa. Phase I (2005) comprised 140 key informant and focus group drug using
interviewees and 19 service providers (SPs), and Phase 2 (2007) comprised 69 drug using focus group
interviewees and 11 SPs.
Results: Drug users put themselves at risk for HIV transmission through various drug-related sexual
practices as well as through needle sharing. Drug users in both phases had limited knowledge of the
availability of drug treatment services, and those that had accessed treatment identified a number of
barriers, including affordability, stigma and a lack of aftercare and reintegration services. SPs identified
similar barriers. Drug users displayed a general awareness of both HIV transmission routes and prevention
strategies, but the findings also indicated a number of misperceptions, and problematic access to materials
such as condoms and safe injection equipment. Knowledge around HIV treatment was low, and VCT
experiences were mixed. SPs recognized the importance o.
Repurposed existing drugs and updated global health policy and clinical guidelines will be essential for limiting the social and economic devastation caused by this virus. So, we are leading a three-phase multinational Network Medicine clinical study (MNM COVID-19 study). The study will apply Network Medicine methodologies to repurpose existing drugs for SARS-CoV-2 infected patients and update global health policy and clinical guidelines.
Presentation on the Access and Delivery Partnership by Tenu Avafia, 3 April 2014.
The presentation covered:
-Impact of NTDs, TB and Malaria on development outcomes;
-Dual challenges of Innovation and Access;
-Government of Japan and UNDP Partnership: Addressing innovation & Access
-Access and Delivery Partnership: strengthening capacity across the health system
Participation of the population in decisions about their health and in the pr...Pydesalud
Póster presentado por Lilisbeth Perestelo en el congreso Summer Institute for Informed Patient Choice (SIIPC14) celebrado del 25 al 27 de junio de 2014 en Dartmouth, Hanover (EEUU). Web: http://siipc.org
Contacto: lperperr@gobiernodecanarias.org
Co-ordinated malaria research for better policy and practice: the role of res...ACT Consortium
Prof. David Schellenberg from the London School of Hygiene & Tropical Medicine presents on behalf of the ACT Consortium at the European Congress on Tropical Medicine and International Health in Basel, Switzerland, 8 September 2015
Global Medical Cures™ | Managing Drug Interactions (Treatment of HIV related ...Global Medical Cures™
Global Medical Cures™ | Managing Drug Interactions (Treatment of HIV related TUBERCULOSIS)
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
Global, regional, and country-level estimates of hepatitisC .docxshericehewat
Global, regional, and country-level estimates of hepatitis
C infection among people who have recently injected
drugs
Jason Grebely1 , Sarah Larney2 , Amy Peacock2 , Samantha Colledge2 , Janni Leung2,3 ,
Matthew Hickman4 , Peter Vickerman4 , Sarah Blach5 , Evan B. Cunningham1 ,
Kostyantyn Dumchev6 , Michael Lynskey7 , Jack Stone4 , Adam Trickey4 , Homie Razavi5 ,
Richard P. Mattick2, Michael Farrell2 , Gregory J. Dore1 & Louisa Degenhardt2
The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia,1 National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia,2 School of Public
Health, Faculty of Medicine, University of Queensland, QLD, Australia,3 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK,4 CDA
Foundation, Lafayette, CO, USA,5 Ukrainian Institute on Public Health Policy, Kiev, Ukraine6 and National Addiction Centre, King’s College London, London, UK7
ABSTRACT
Background and Aims People who have recently injected drugs are a priority population in efforts to achieve hepatitis C
virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living
with HCV, and the proportion of people with recent injecting drug use among all people living with HCV infection at global,
regional and country-levels. Methods Data from a global systematic review of injecting drug use and HCV antibody
prevalence among people with recent (previous year) injecting drug use were used to estimate the prevalence and number
of people with recent injecting drug use living with HCV. These datawere combined with a systematic review of global HCV
prevalence to estimate the proportion of people with recent injecting drug use among all people living with HCV.
Results There are an estimated 6.1 million [95% uncertainty interval (UI) = 3.4–9.2] people with recent injecting drug
use aged 15–64 years living with HCV globally (39.2% viraemic prevalence; UI = 31.6–47.0), with the greatest numbers
in East and Southeast Asia (1.5 million, UI = 1.0–2.1), eastern Europe (1.5 million, UI = 0.7–2.4) and North America (1.0
million, UI = 0.4–1.7). People with recent injecting drug use comprise an estimated 8.5% (UI = 4.6–13.1) of all HCV
infections globally, with the greatest proportions in North America (30.5%, UI = 11.7–56.7), Latin America (22.0%,
UI = 15.3–30.4) and eastern Europe (17.9%, UI = 8.2–30.9). Conclusions Although, globally, 39.2% of people with
recent injecting drug use are living with hepatitis C virus (HCV) and 8.5% of all HCV infections occur globally among
people with recent injecting drug use, there is wide variation among countries and regions.
Keywords Estimates, HCV, IDU, injecting drug use, PWID, viraemic.
Correspondence to: Jason Grebely, The Kirby Institute, Level 6, Wallace Wurth Building, UNSW Sydney, Sydney, NSW 2052, Australia.
E-mail: [email protected]
Submitted 8 January 2018; initial review completed 29 March 2018; final version accepted 12 J ...
The Transtheoretical Model also called the Stages
of Change model,7 describes how such behavior
change often occurs. The model emphasizes the
need to understand the experience of the person we
are trying to reach in order to help them. To promote
change, interventions must be provided that are
appropriate for the stage in the process that people
are in."
"Meet people where they are:
The guiding principle of “meeting people where
they are” means more than showing compassion
or tolerance to people in crisis. This principle also
asks us to acknowledge that all people we meet are
at different stages of behavior change."
NIH AIDS Executive Committee (NAEC) FY 2019 Ending the HIV Epidemic (EHE) in ...HopkinsCFAR
The NIH Office of AIDS Research (OAR) is pleased to release the NIH AIDS Executive Committee (NAEC) FY 2019 Ending the HIV Epidemic (EHE) in the U.S. Report.
NIMH funding on PrEP use Among Adolescent Girls and Young Women in sub-Sahara...HopkinsCFAR
Dr. Susannah Allison. Dr. Allison is a Program Officer at the National Institute of Mental Health within the Division of AIDS Research. She oversees a portfolio of research focused on the prevention of HIV infection among infants, children, and adolescents as well as research to enhance health outcomes among youth living with HIV. She is also the training director for the division. Prior to working at NIMH, Dr. Allison worked with children and families infected and affected by HIV in Baltimore, Miami, and Washington, DC. She completed her doctorate at George Washington University where she received her Ph.D. in Clinical Child Psychology with an emphasis in child health psychology.
High Sensitivity HIV Testing and Translational Science around PrEPHopkinsCFAR
Joanne Stekler, MD MPH
Associate Professor, Department of Medicine
University of Washington
Inter-Center for AIDS ResearchAntiretroviralsfor Prevention Working Group
November 13, 2017
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
Operation “Blue Star” is the only event in the history of Independent India where the state went into war with its own people. Even after about 40 years it is not clear if it was culmination of states anger over people of the region, a political game of power or start of dictatorial chapter in the democratic setup.
The people of Punjab felt alienated from main stream due to denial of their just demands during a long democratic struggle since independence. As it happen all over the word, it led to militant struggle with great loss of lives of military, police and civilian personnel. Killing of Indira Gandhi and massacre of innocent Sikhs in Delhi and other India cities was also associated with this movement.
How to Make a Field invisible in Odoo 17Celine George
It is possible to hide or invisible some fields in odoo. Commonly using “invisible” attribute in the field definition to invisible the fields. This slide will show how to make a field invisible in odoo 17.
We all have good and bad thoughts from time to time and situation to situation. We are bombarded daily with spiraling thoughts(both negative and positive) creating all-consuming feel , making us difficult to manage with associated suffering. Good thoughts are like our Mob Signal (Positive thought) amidst noise(negative thought) in the atmosphere. Negative thoughts like noise outweigh positive thoughts. These thoughts often create unwanted confusion, trouble, stress and frustration in our mind as well as chaos in our physical world. Negative thoughts are also known as “distorted thinking”.
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
2024.06.01 Introducing a competency framework for languag learning materials ...Sandy Millin
http://sandymillin.wordpress.com/iateflwebinar2024
Published classroom materials form the basis of syllabuses, drive teacher professional development, and have a potentially huge influence on learners, teachers and education systems. All teachers also create their own materials, whether a few sentences on a blackboard, a highly-structured fully-realised online course, or anything in between. Despite this, the knowledge and skills needed to create effective language learning materials are rarely part of teacher training, and are mostly learnt by trial and error.
Knowledge and skills frameworks, generally called competency frameworks, for ELT teachers, trainers and managers have existed for a few years now. However, until I created one for my MA dissertation, there wasn’t one drawing together what we need to know and do to be able to effectively produce language learning materials.
This webinar will introduce you to my framework, highlighting the key competencies I identified from my research. It will also show how anybody involved in language teaching (any language, not just English!), teacher training, managing schools or developing language learning materials can benefit from using the framework.
Palestine last event orientationfvgnh .pptxRaedMohamed3
An EFL lesson about the current events in Palestine. It is intended to be for intermediate students who wish to increase their listening skills through a short lesson in power point.
How to Create Map Views in the Odoo 17 ERPCeline George
The map views are useful for providing a geographical representation of data. They allow users to visualize and analyze the data in a more intuitive manner.
3. 3
NIDA HIV/AIDS FY13 Program Profile
17%
16%
1%
3% 4% 2%
55%
Behavioral and
Social Science
Natural History &
Epidemiology
Etiology &
Pathogenesis
Vaccines
Therapeutics
Training Other
4. NIDA HIV/AIDS Budget by Research Area
Natural History and Epidemiology-------------- $44M
Etiology and Pathogenesis----------------------- $41M
Microbicides----------------------------------------- $0
Vaccines---------------------------------------------- $4M
Behavioral and Social Science----------------- $188M
Therapeutics----------------------------------------- $8M
Training, Infrastructure, and
Capacity Building------------------------------ $13M
Information Dissemination----------------------- $2M
4
5. On Nov. 2013, Dr. Collins charge to OAR’s Advisory
Council “Produce a report that outlines the highest
priority AIDS research in 3 areas”
• Prevention - including vaccines, microbicides, ARV-based
prevention, behavioral research focused on risk reduction,
stigma, and adherence
• Treatment - including advances in therapeutic interventions
and research toward a cure
• Co-morbidities - neurologic, cardiovascular, oncologic, and
accelerated aging
The document should also identify priorities that cut across the
above mentioned areas with regard to basic science, training,
and information dissemination.
6. OAR Priority Report (June, 2014)
• Prevention
Vaccines, microbicides, PrEP,
Integrated Strategies (combination)
• Treatment: Anti-retroviral
Therapy
More efficient Tx
• The Prevention and Care
Continua
STTR
• Cure Animal models, latency, reservoirs
• Co-infection, Co-morbidities, &
complications TB, HCV, cardio, kidney,
neuro, & aging (in presence of HIV)
• Basic Science
System Bio, Animal models
• Behavioral & Social Sciences
Innovative methods, comparative
effectiveness
• Implementation Science
Access, uptake, retention, scale-up,
Sustainability
• Training, infrastructure, and
Capacity-building
• Information Dissemination
7. Managing NIH HIV/AIDS Program
Proactively
• OAR approval of all FOAs
• Review of HIV/AIDS relatedness of
Applications (CSR)
• Develop Trans-NIH definition of what is
HIV/AIDS research
• Develop trans-NIH policy for proportional
funding (Prorate)
Next step: Portfolio review to identify low priority grants
8. FY15 & FY16 Priorities
Promoting Retention in HIV Care
HIV Prevention in Vulnerable Populations in the U.S.—Emphasis on youth, the
Homeless and Black/African American Women and Young Black/African
American Men
Developing Comprehensive Interventions for Substance Using MSM
Implementation Science Research
Transformative Research
Prevention and Treatment of HCV in those with and at Risk for HIV
Enhancing Treatment as Prevention through Use of Incentives and Technology
Training, Infrastructure, and Capacity Building
9. FY15 Initiatives
Avant-Garde RFA (DP1)
A-START PAR (R03/$100K)
NIDA/ANRS Fellowship ($75K)
Advancing exceptional HIV/AIDS Research RFA (R01)
Extracellular Vesicles in HIV/AIDS and Substance Abuse RFA (R21, R01)
NIDA Drug Abuse and HIV Cohorts PAR (U01)
Technology-Based Interventions to Promote Engagement in Care & Tx
Adherence & For Substance Abusing Populations with HIV PA (R01,R34)
HIV, Drugs, & Vulnerable Pop PA (R21, R01)
AVENIR (AIDS) RFA (DP2)
10. FY15 Initiatives (Cont.)
Substance Use & Abuse, Risky Decision Making & HIV/AIDS PA (R03, R21, R01)
Centers for AIDS Research & Developmental Centers for AIDS Research PA (P30)
Drug Abuse Aspects of HIV/AIDS PA (R03, R21, R01)
Prevention & Tx of HCV in Those with and at Risk for HIV PAR (R21, R01, R34)
Long-Term Retention in Care for US Substance Using Pops PA (R01, R21, R34)
International Research Collaboration on Drug Abuse & Addiction Research (R21,
R01)
Development and Testing of Novel Interventions to Improve HIV Prevention, Care,
and Program Implementation PA (R34)
Note: NIDA has also joined many other ICS’ FOAs
11. FY16 Initiatives
Avant-Garde RFA (DP1)
A-START PAR (R03/$100K)
NIDA/ANRS Fellowship ($75K)
Advancing exceptional HIV/AIDS Research RFA (R01)
AVENIR (AIDS) RFA (DP2)
Substance Use & Abuse, Risky Decision Making & HIV/AIDS PA
(R03, R21, R01)
Centers for AIDS Research & Developmental Centers for AIDS
Research PA (P30)
12. FY16 Initiatives (Cont.)
Drug Abuse Aspects of HIV/AIDS PA (R03, R21, R01)
Prevention & Tx of HCV in Those with and at Risk for HIV PAR
(R21, R01, R34)
Long-Term Retention in Care for US Substance Using Pops PA
(R01, R21, R34)
International Research Collaboration on Drug Abuse & Addiction
Research (R21, R01)
Development and Testing of Novel Interventions to Improve HIV
Prevention, Care, and Program Implementation PA (R34)
Note: NIDA has also joined many other ICS’ FOAs
13. New FY16 Initiatives
Role of Polysubstance use in HIV Cure/Remission
Research: Novel Approaches RFA (R03, R21, R01)
Integration of Infectious Diseases and Substance Abuse
Treatment for HIV Positive Patients RFA (R01 & R34)
Enhancing Seek, Test, Treat, & Retain Strategies for
Substance Using Adolescents and Young Adults RFA (R01)
14. Role of Polysubstance use in HIV
Cure/Remission Research: Novel Approaches
• Goals: Provide basic/clinical research
evidence on specific role of polySU that
may be most critical in HIV pathophysiology
• NIH Towards the cure—emphasis on virus
in primary peripheral sites (CD4+ and other
immune cells)
• This RFA will emphasize two critical areas:
– 1) Towards a cure in brain (in vivo
emphasis with in vitro components)
– 2) Towards a cure in substance using
populations (periphery)
• Critical research on reservoirs within
macrophage, microglia, and astrocytes
15. Integration of Infectious Diseases and
Substance Abuse Treatment for HIV Positive
Patients
Goals
To develop and evaluate comprehensive integrated treatment
services for HIV and co-infections among substance abusers
Support implementation research to determine how to best
provide comprehensive, integrated effective preventive and
treatment interventions that are scalable, sustainable, and
cost-effective in diverse populations
Note: This initiative can provide data on the beneficial health effects of drug
treatment on other than HIV outcomes
16. Enhancing Seek, Test, Treat, & Retain Strategies for
Substance Using Adolescents and Young Adults
• Target US youth age 14-25
• Prioritize intervention studies that
recruit highest risk youth &
address developmental, legal
and service delivery issues
– Lead to improvements in
serostatus knowledge, linkage to
care/retention, & achievement of
undetectable viral loads.
Estimated Cascade of Care among
HIV+ Youth
in the US (age 13-29)
17. Topics Under Consideration
Cascade of Care Retention Gap
Combination HIV Prevention Strategy
Alcohol, drug abuse, and HIV
Functional collaboration with NIAAA
STTR/TasP
17
